Rockwell Medical (NASDAQ:RMTI) has completed its New Drug Application (NDA) submission to the FDA for the Intravenous (I.V.) formulation of Triferic.
Triferic is the only FDA-approved therapy indicated to replace iron and maintain hemoglobin in hemodialysis patients via dialysate during each dialysis treatment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.